Effect of homocysteine lowering for the prognosis of frail patients with heart failure

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050420

Enrollment

Unknown

Registered

2021-08-27

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Experimental group:Medication to reduce homocysteine level + Conventional medication

Control group:Conventional medication + placebo

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 60 years; 2. Comply with the Chinese Heart Failure Diagnosis and Treatment Guidelines 2018; 3. HCY >= 15µmol/L; 4. Use the frailty phenotype to diagnose frail patients; 5. Patients who agree and can cooperate with the completion of this study.

Exclusion criteria

Exclusion criteria: 1. Patients with unstable, critical and terminal disease; 2. Patients with cognitive dysfunction, disturbance of consciousness, mental illness and other diseases; 3. Completely disabled or bedridden patients; 4. Patients with definite diagnosis of tumor or patients with severe liver and kidney insufficiency; 5. Patients with heart valve disease, congenital heart disease and other heart structural diseases that require surgical treatment, but have not undergone surgical treatment.

Design outcomes

Primary

Measure	Time frame
Main adverse cardiovascular events (MACE);Serum homocysteine;Left ventricular ejection fraction (LVEF);Diastolic dysfunction index;	—

Countries

China

Contacts

Public ContactLiu Zhenbing

Ordos Central Hospital

LZHBL44@126.COM+86 13624774699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026